Hydrogen Mobility Europe (H2ME) deploys its first 100 zero-emission vehicles across Europe
Hydrogen Mobility Europe (H2ME) – the ambitious multi-country, multi-partner project to demonstrate that hydrogen can support Europe’s future transport demands – today announced that the first 100 fuel cell electric vehicles (FCEVs) deployed by H2ME are now on the road in Germany, France and the UK.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170208005016/en/
A new generation of fuel-efficient vehicles
H2ME brings together eight European countries to address the actions required to make the hydrogen mobility sector truly ready for market. The largest-scale project of its kind, H2ME will:
- Perform large-scale market tests of hydrogen refuelling infrastructure;
- Deploy hundreds of passenger and commercial fuel cell electric vehicles operated in real-world customer applications;
- Demonstrate the system benefits generated by using electrolytic hydrogen solutions in grid operations.
Sixty of Symbio’s Renault Kangoo ZE-H2 range-extended fuel cell vans have been deployed in the UK and France, supporting the development of a network of hydrogen refuelling stations in those markets. Powered by a compact 5 kW fuel cell module, coupled with a hydrogen storage unit and medium-size automotive battery pack, Symbio’s range-extender kit doubles the range of Renault’s electric-only Kangoo ZE model to 320 Km.
In addition, Daimler has deployed 40 B-Class F-CELL vehicles under H2ME in Germany. Thanks to the 700-bar, high-pressure fuel-tank system, the car has a long operating range of around 400 kilometres and can be refuelled in less than three minutes. The vehicle’s electric motor develops an output of 100 kW and, with a torque of 290 Nm, the car combines local emission-free mobility with day-to-day suitability and good performance figures.
The new vehicles are exciting the market with the potential of a new generation of fuel-efficient, zero-emission vehicles. For CETUP, a logistics and delivery company, the Renault Kangoo ZE-H2 equipped by Symbio is a welcome addition to the fleet. It reduces overall fuel dependence and emissions, while providing the smooth ride and power necessary to keep the business moving forward. Symbio noted that in specialised markets where zero emissions and guaranteed daily operation are critical, Kangoo ZE-H2 customers are winning new business over competition. To perform last-mile delivery in cities that prohibit polluting transport, hydrogen provides unique features compared to pure battery-based utility vehicles. To illustrate, last September, CETUP’s Kangoo ZE-H2 equipped by Symbio broke a range record by covering 367 km at once with a fully loaded battery and a full hydrogen tank.
A promising technology for the future
In the coming years, the H2ME project will deploy partners’ next-generation FCEVs, including: Symbio’s next-generation FC RE-EV (Fuel Cell Range Extender Electric Vehicle) vans and Symbio Fuel Cell range-extended trucks; Honda’s second-generation FCEV; and Daimler’s next-generation Mercedes-Benz GLC F-CELL, which includes the additional energy source of a large lithium-ion battery and will feature external charging by plug-in technology for the first time. In total, more than 1,400 FCEVs will be deployed as part of the H2ME project throughout the UK, France, Germany, the Netherlands and Scandinavia. The aim is to increase the number of FCEVs operating on Europe’s roads to build on the strong networks of hydrogen refuelling stations created by H2ME and other initiatives across the EU.
Recognised by the EU as critical to solving Europe’s environmental and economic challenges, fuel cell vehicles have been identified as a promising technology to lower emissions and improve energy security with minimal impact on the driver in terms of functionality or convenience.
“Symbio is proud to be part of the hydrogen momentum in Europe and contribute to a low-carbon economy by facilitating the deployment of 100% zero-emission and 100% electric vehicles,” said Pierre-Yves Le-Berre, VP, Symbio. “Electric vehicles integrated with Symbio’s range extender are able to reduce air pollution in urban areas. Our ambition is to equip all urban delivery centres with our vehicles to guarantee the absence of harmful emissions, as well as address new market trends and regulations. For instance, if a delivery centre used a Renault Kangoo equipped with our range extender, driving 200 km a day in Paris, it would remove the carbon emissions of 20 private vehicles.”
“Vehicles such as the B-Class F-CELL and the Citaro FuelCELL-Hybrid urban bus have covered altogether more than 12 million kilometres to date, proving the market readiness of this power train,” said Dr Georg Frank, Senior Manager Fuel Cell Advanced Engineering and H2-Infrastructure at Daimler AG. “Now we strongly continue to pursue our goal of bringing the next-generation fuel cell electric vehicles, based on the Mercedes-Benz GLC, to the market. But the big breakthrough of electric mobility with fuel cell depends on more than just the factor ‘car’: it is ultimately the combination of an attractive product offer, infrastructure, services, and not least, public support. The last hurdles we will have to overcome in intensive cross-industry and cross-border teamwork – H2ME is a very good example of it.”
Ben Madden, Element Energy, Overall Coordinator of the H2ME projects , said, “H2ME is delighted to see its first 100 fuel cell vehicles now on the road in three critical European markets. To start the transition to a zero-emission transportation system it is essential to put the latest technology in drivers’ hands and use the hydrogen demand created to develop and test the refuelling networks, which are required to support these vehicles. We are proud of the rapid progress our partners have made in deploying this technology, which can accelerate Europe’s move to clean transportation.”
Notes to editors:
This €170 million demonstration project is co-funded with €67 million from the Fuel Cells and Hydrogen Joint Undertaking (FCH JU), a public-private partnership supporting fuel cell and hydrogen energy technologies in Europe.
Partners include project lead Element Energy, alongside AGA, Air Liquide Advanced Business, Air Liquide Advanced Technologies, AREVA H2GEN, Audi, BOC, BMW, Cenex, City of Copenhagen (Kobenhavns Kommune), Communauté d’Agglomération Sarreguemines Confluence, Communauté Urbaine Du Grand Nancy, CNR, Daimler AG, Danish Hydrogen Fuel, EIFER, Falkenberg Energi, GNVERT, H2 Logic, H2 Mobility Deutschland, Honda, Hydrogene de France, HYOP, hySOLUTIONS, Icelandic New Energy Ltd, Islenska Vetnisfelagid (H2 Iceland), ITM Power, Linde AG, McPhy Energy, Michelin, Netherlands Ministry of Infrastructure and the Environment (Ministerie Van Infrastructuur en Milieu), Nissan, OMV, OPEN ENERGI, Renault, Renault Trucks, SEMITAN, Stedin, STEP, Symbio FCell, The Danish Partnership for Hydrogen and Fuel Cells (Partnerskab for brint of braensdels cellar), The University of Manchester, WaterstofNet.
About the FCH JU
The Fuel Cells and Hydrogen Joint Undertaking (FCH JU) is a unique public-private partnership supporting research, technological development and demonstration activities in fuel cell and hydrogen energy technologies in Europe. Its aim is to accelerate the market introduction of these technologies, realising their potential as an instrument in achieving a carbon-lean energy system.
The three members of the FCH JU are the European commission; the fuel cell and hydrogen industries, represented by the NEW industry grouping; and the research community, represented by research grouping N.ERGHY.
This project has received funding from the Fuel Cells and Hydrogen Joint Undertaking under grant agreement No 671438 and No 700350. This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation programme, Hydrogen Europe, and the New European Research Grouping on Fuel Cells and Hydrogen (“N.ERGHY”).
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 201711.12.2017 13:00 | Pressemelding
2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer. External partnerships complement Boehringer Ingelheim’s two-pronged research strategy – investigating both cancer cell-directed therapies and immune cell-directed therapies. This multi-faceted approach offers the potential to bring innovative opportunities to the Boehringer Ingelheim oncology portfolio and novel therapies to patients. “Immuno-oncology is radically shifting the research and treatment landscape in oncology. We believe that the greatest success in difficult-to-treat cancers will be achieved with immuno-oncology and its combination with cancer cell directed therapy, which is why we are committing significant resources in both areas,” said Jonathon Sedgwick, Ph.D., Vice
Valence Advises SK Capital on Its Acquisition of ICL’s Fire Safety and Oil Additives Businesses11.12.2017 12:47 | Pressemelding
The Valence Group acted as lead financial advisor to SK Capital Partners on its announced acquisition of the Fire Safety and Oil Additives businesses of Israel Chemicals Ltd. (“ICL”) for approximately $1 billion. The transaction is expected to close during the first half of 2018. The Businesses, headquartered in St. Louis, Missouri, have global operations and are market leaders in each of their segments. The ICL Fire Safety business is a formulator and manufacturer of fire management chemicals. Its Phos-Chek fire retardants, Class A and B foams, and water enhancing gels are the world’s leading chemical solutions for managing wildland, military, industrial and municipal fires, and are used in partnership with fire management agencies across the globe. The ICL Oil Additives business provides high quality phosphorus pentasulfide used in the preparation of ZDDP-based lubricant additives, i
Smith & Nephew Announce European Launch of Handheld Imaging Technology Heralding a New Era of Evidence-Based Decision Making in Wound Care11.12.2017 10:18 | Pressemelding
Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the European launch of MolecuLight i:X TM, the easy to use, handheld imaging device that instantly measures wound surface area and visualises the presence and distribution of potentially harmful bacteria in wounds.2,3 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211005434/en/ Currently wound assessments are made with the naked eye which can lack the accuracy required to most effectively guide clinical decision making.4 Using fluorescence, MolecuLight i:X quickly, safely, and easily visualises potentially harmful bacteria1,2,3 in wounds which may otherwise lack signs or symptoms of infection. It enhances a clinician’s ability to choose the right therapy, at the right time for their patient1,
Dr Amal Al Qubaisi Wins Parliamentarian Excellence Award as Best President of Arab Parliament11.12.2017 09:41 | Pressemelding
The Arab Inter-Parliamentary Union (AIPU) has honored Her Excellency Dr Amal Al Qubaisi, Speaker of the Federal National Council (FNC) – the United Arab Emirates parliament, with the Parliamentarian Excellence Award in the Presidents of Arab Parliaments category. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211005411/en/ Her Excellency Dr Amal Al Qubaisi, Speaker of the Federal National Council (FNC) – the UAE parliament (Photo: AETOSWire) The award honors Al Qubaisi as ‘first female leader of a parliament in the Arab world’, celebrating her achievements on a national, regional and global scale, as well as the accomplishments made by FNC under her leadership. It also acknowledges the pioneering parliamentarian initiatives, projects and programs she has spearheaded and her significant contr
Financial Market Regulator Grants EU Payment License to DIMOCO Payment Services11.12.2017 08:00 | Pressemelding
The Austrian Financial Market Authority (FMA) granted a license under the Payment Service Act to DIMOCO Payment Services . The awarded license allows DIMOCO Payment Services to contribute to the payment value chain, offering merchants a single technical interface and a unified clearing & settlement process for many payment methods, including credit cards, online bank transfers, SEPA and direct debit cards. “We differ from most PSPs in the global payments ecosystem with our personal touch,” said Boris Kersten, Managing Director of DIMOCO Payment Services. “We proactively and personally monitor the overall payment process. In addition to monitoring individual transactions, we make recommendations and take actions to decrease chargebacks and fraudulent transactions. This process is not simply left to algorithms, the human element is added to the mix resulting in the protec
Top UK university hospital unveils data that support the use of rapid infusion for Truxima® (CT-P10, biosimilar rituximab) in patients with advanced-stage follicular lymphoma11.12.2017 08:00 | Pressemelding
New data from University College London Hospitals NHS Foundation Trust (UCLH) on the safety and tolerability of rapid infusion of CT-P10 were presented this weekend at the 59th American Society of Hematology (ASH) Annual Meeting. The results showed that rapid infusion of CT-P10 was well-tolerated across all patient groups and patients could be safely switched from reference rituximab to CT-P10 without reverting to slower infusion rates1. The independent study examined the infusion-related reactions (IRRs) in three different patient groups: rituximab naive, those switching directly from reference rituximab to CT-P10, and those that received their last dose of reference rituximab at least 6 months prior to the study.1 The administration of rituximab is associated with IRRs which occur most frequently during the first infusion. To reduce the risk of IRRs, it is the man
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom